Ask AI
Newly Diagnosed Multiple Myeloma

CE / CME

What’s New in Newly Diagnosed Multiple Myeloma

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: May 16, 2024

Expiration: May 15, 2025

Activity

Progress
1
Course Completed

Introduction

In this module, Charise Gleason, MSN, NP-C, AOCNP, discusses recent safety and efficacy data on multidrug regimens for the management of transplant-eligible and transplant-ineligible patients with newly diagnosed (ND) multiple myeloma (MM). She also provides guidance on managing key adverse events (AEs) with MM treatments.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. The question will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your response will be aggregated for analysis, and your specific response will not be shared.

For those providing patient care, how many patients with MM do you provide care for in a typical month?

What induction therapy would you recommend for this patient?

In the phase III IsKia EMN24 trial that enrolled transplant-eligible patients with NDMM, which of the following was reported with isatuximab/carfilzomib/lenalidomide/dexamethasone (IsaKRd) vs carfilzomib/lenalidomide/dexamethasone (KRd)?

What therapy would you recommend for this patient?

For a patient with NDMM receiving a quadruple-drug regimen with Dara-VRd who develops a deep vein thrombosis (DVT) despite adhering to a daily 81 mg aspirin regimen, what would be the most appropriate thromboprophylaxis strategy moving forward?